



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Bavituximab

Cat. No.:	HY-P99279
CAS No.:	648904-28-3
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Bavituximab (Anti-Human Phosphatidylserine Recombinant Antibody) is a phosphatidylserine (PS)-targeting monoclonal antibody, suppresses tumor growth by targeting tumor vasculature and reactivating antitumor immunity. Bavituximab plus Paclitaxel (HY-B0015) and Carboplatin (HY-17393), have enhanced inhibition on non-small-cell lung cancer ^[1] .									
IC₅₀ & Target	Phosphatidylserine (PS) ^[1]									
In Vitro	<p>Bavituximab binds to exposed phosphatidylserine (PS) molecules via the serum protein, β2-glycoprotein 1 (β2GP1)^[1]. Bavituximab binds PS to induces antibody-dependent cellular cytotoxicity, resulting in tumor vessel destruction^[1]. Bavituximab (10 μg/mL; 48 h) binds to exposed phosphatidylserine (PS) via 10 μM Sorafenib inducing exposure in HUVEC and bEnd.3 cells^[2].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>									
In Vivo	<p>Sorafenib induces exposure of anionic phospholipids in tumor model in mice. Bavituximab (100 μg/mouse; i.v.; single dose; 48 h after Sorafenib treatment) traces phosphatidylserine exposure in vivo^[2].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Animal Model:</td> <td>Mice bearing subcutaneous PLC/PRF/5, C3A, and Huh7 tumors^[2]</td> </tr> <tr> <td>Dosage:</td> <td>100 μg/mouse (Bavituximab/β2GP1)</td> </tr> <tr> <td>Administration:</td> <td>Intravenous injection single dose; 48 h after sorafenib treatment (100 mg/kg; p.o.; single dose)</td> </tr> <tr> <td>Result:</td> <td>Traced phosphatidylserine exposure in vivo in mice with tumors.</td> </tr> </table>		Animal Model:	Mice bearing subcutaneous PLC/PRF/5, C3A, and Huh7 tumors ^[2]	Dosage:	100 μ g/mouse (Bavituximab/ β 2GP1)	Administration:	Intravenous injection single dose; 48 h after sorafenib treatment (100 mg/kg; p.o.; single dose)	Result:	Traced phosphatidylserine exposure in vivo in mice with tumors.
Animal Model:	Mice bearing subcutaneous PLC/PRF/5, C3A, and Huh7 tumors ^[2]									
Dosage:	100 μ g/mouse (Bavituximab/ β 2GP1)									
Administration:	Intravenous injection single dose; 48 h after sorafenib treatment (100 mg/kg; p.o.; single dose)									
Result:	Traced phosphatidylserine exposure in vivo in mice with tumors.									

REFERENCES

[1]. Digumarti R, et al. Bavituximab plus paclitaxel and carboplatin for the treatment of advanced non-small-cell lung cancer. Lung Cancer. 2014 Nov;86(2):231-6.

[2]. Cheng X, et al. Antibody-Mediated Blockade of Phosphatidylserine Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinomas Xenografts. Ann Surg Oncol. 2016 Dec;23(Suppl 5):583-591.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA